Trials / Completed
CompletedNCT02995096
Tumor Characteristics, Pre-transplant Treatments and Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma
The Effect of Tumor Characteristics, Pre-transplant Treatments and Immunosuppression on Survival After Liver Transplantation for Hepatocellular Carcinoma - a European Registry Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 23,124 (actual)
- Sponsor
- Rigshospitalet, Denmark · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Recurrence after liver transplantation for hepatocellular carcinoma (HCC) represents an important cause of mortality for this surgical population. In addition to tumor characteristics, It has been suggested that pre-treatment and sirolimus-based immunosuppression may affect recurrence and survival. With data from the European Liver Transplant Registry (ELTR) database, the aim of this study is to investigate the impact of tumor characteristics, pre-transplant treatment and immunosuppression regimens on survival after liver transplantation for HCC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Pre-treatment | Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization) |
| DRUG | Sirolimus based immunosuppression | Immunosuppression regimens containing Sirolimus |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2018-10-01
- Completion
- 2019-03-01
- First posted
- 2016-12-16
- Last updated
- 2019-04-02
Source: ClinicalTrials.gov record NCT02995096. Inclusion in this directory is not an endorsement.